Posts by
The first biosimilar was launched in 2006, but it is only now that the explosion of biosimilars into the market seems guaranteed. With the imminent or recent patent expiry of a range of biologics in oncology, rheumatoid arthritis and diabetes the scene is set for a dynamic influx of biosimilars that promise patients and healthcare...
Read More: The Future’s Bright – the Future’s BiosimiliarHaving lived with Brexit now for two years, and most of the nation is bored yet fascinated (and somewhat fearful), the impact of a no deal or an extended negotiation is a real and present issue. With Brexit in seeming turmoil at this point (late 2018) a robust solution to maintain the availability of medicines...
Read More: Brexit and the pharmaceutical industryFor UK scientific and medical research to thrive, it is imperative that the UK can attract and retain the finest scientific minds, this is an undisputed fact. The ability for the UK to compete on an international stage is dependent on our ability to attract excellent international talent. The Royal Society outlines that 17% of...
Read More: Safeguarding the UK as a scientific superpower – what does Brexit mean?Spanish flu a bigger Grim Reaper than the First World War 2018 is the centenary of the most deadly killer in recent memory……. You may be surprised to hear that this statement isn’t referring to the First World War but the pandemic infection known as the Spanish flu. Spanish flu came in three waves in...
Read More: Spanish flu…remembering and considering if such a thing could happen again
